Anamorelin Efficacy in Non-Small-Cell Lung Cancer Patients With Cachexia: Insights From ROMANA 1 and ROMANA 2

What Was Tested

This randomized controlled trial paper looks at Ghrelin and Anamorelin (non-peptide).

NCT identifiers: ROMANA 1: NCT01387269; ROMANA 2: NCT01387282.

Who Took Part

According to the abstract, 3 people were involved.

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Ghrelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the people and researchers unaware of who received Ghrelin.

Some people received a placebo instead of Ghrelin, giving a reference point.

The timeline in the abstract includes 6 months.

What Was Measured

Topics PubMed links to this paper include Body Composition, Body Mass Index, Cachexia, Carcinoma, Non-Small-Cell Lung, Hydrazines, Lung Neoplasms and Oligopeptides.

Author keywords: ROMANA 1, ROMANA 2, cancer, modified Glasgow Prognostic Score, systemic inflammatory response and trials.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Ghrelin and Anamorelin (non-peptide) in 3 people over 6 months.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (Journal of cachexia, sarcopenia and muscle), a journal based in Germany.

More context: the Ghrelin compound page and the Anamorelin (non-peptide) compound page, all human trials.